 |
|
Analysis shows that vidaza prolongs survival in patients with higher-risk myelodysplastic syndromes
December 11, 2008The Myelodysplastic Syndromes (MDS) Foundation announced today that a subanalysis of the AZA-001 phase III international clinical trial shows that treatment with VIDAZA (azacitidine) can extend overall survival and reduce the risk of death in elderly higher-risk MDS patients.
Dr. John F. Seymour of the Peter MacCallum Cancer Institute in Victoria, Australia presented the analysis at the 50th Annual Meeting of the American Society of Hematology in San Francisco. The results showed that 55 percent of patients in the trial had significantly higher overall survival rates at two years when treated with VIDAZA, as compared to patients treated with conventional care regimens (CCR).
"Dr. Seymour's analysis shows the major recent clinical advancements in treatments for elderly, higher-risk MDS patient," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation. "We are hopeful about the potential of new therapies, like VIDAZA, which are helping MDS patients to live longer and with a better quality of life."
The analysis presented by Dr. Seymour is a follow-up to results from the AZA-001 trial, presented at the American Society of Clinical Oncology meeting in June, which showed that VIDAZA significantly extends overall survival for patients with MDS compared to conventional care regimens. Patients who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.
MDS Foundation
The analysis presented by Dr. Seymour is a follow-up to results from the AZA-001 trial, presented at the American Society of Clinical Oncology meeting in June, which showed that VIDAZA significantly extends overall survival for patients with MDS compared to conventional care regimens. Patients who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.
MDS Foundation
Myelodysplastic Syndromes Current Events and Myelodysplastic Syndromes News RSSAnemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).
Study of revlimid and vidaza in higher-risk MDS is well-tolerated and has high activity
Celgene International Sarl (NASDAQ: CELG) reported that results of a Phase I study presented today combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well tolerated and has high activity.
Data presented demonstrate prolonged overall survival for patients with acute myeloid leukemia
The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).
Research on the effects of stem cell source and patient age on transplantation outcomes
Blood cancers - leukemia, lymphoma, and myeloma - are typically treated with a combination of treatments including chemotherapy, biological therapy, radiation therapy, and stem cell transplantation. Stem cell transplantation is the process by which blood stem cells are collected from a donor, or from the patient prior to chemotherapy, and then infused into the patient after treatment.
Avoiding Spleen Removal for Cooley's Anemia Sufferers
Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia.
NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
Researchers at the National Sun Yat-Sen University and Kaohsiung Medical University, Kaohsiung, Taiwan have revealed a new mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) attenuate tumor invasion and metastasis.
Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
A new scoring system for a form of leukemia known as myelodysplastic syndrome (MDS) identifies patients who appear to have low-risk disease but actually have poor prospects of survival, researchers at The University of Texas M. D. Anderson Cancer Center report online at the journal Leukemia.
Role for proteomics in identifying hematologic malignancies
Scientists have identified a set of biomarkers that could help clinicians identify a group of hematologic malignancies known as myelodysplastic syndromes (MDS), which affect approximately 300,000 individuals worldwide and often progress to acute myeloid leukemia.
More Myelodysplastic Syndromes Current Events and Myelodysplastic Syndromes News Articles
 |
100 Questions & Answers About Myelodysplastic Syndromes by Jason Gotlib (Author) MDS is a lethal blood disease that affects as many as 50 per 100,000 individuals over the age of 70. The disorder is five times more prevalent than AML, a form of leukemia. Whether you're a newly diagnosed patient, a survivor, or loved one of someone suffering from MDS, this book offers help. The only text available to provide both the doctor's and patient's views, 100 Questions & Answers About Myelodysplastic Syndromes, provides practical, authoritative answers to 100 of the most common questions asked. Written with commentary from actual patients, this is an invaluable resource for anyone struggling with the medical, physical, and emotional turmoil of this disease. |
 |
Myelodysplastic Syndromes: Pathobiology and Clinical Management, Second Edition (Basic and Clinical Oncology) by David P. Steensma (Editor) Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition. An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features: a new eight-page color insert 200 color and black-and-white illustrations reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field New... |
 |
Fight Against Myelodysplastic Syndromes Long Sleeve T-shirt Large White by Shop Zeus |
 |
Fight Against Myelodysplastic Syndromes Keychain by Design a Product LLC Text on keychain: Fight Against Myelodysplastic Syndromes * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
 |
21st Century Ultimate Medical Guide to Myelodysplastic Syndromes (Preleukemia, Smoldering Leukemia) - Clinical Information for Physicians and Patients, Treatment Options (Two CD-ROM Set) by PM Medical Health News (Author) This up-to-date and comprehensive set of two CD-ROM discs provides a superb collection of official Federal government documents on myelodysplastic syndromes: signs and symptoms, diagnosis, lab tests, treatment and management options, and ongoing clinical research. Every aspect of the disease is thoroughly covered. Myelodysplastic syndromes are a group of diseases in which the bone marrow does not make enough healthy blood cells. Also called preleukemia and smoldering leukemia. For patients, practical information is provided in clearly written patient education documents. For medical professionals, doctor references and texts have detailed technical information and clinical background material. Documents from the National Cancer Institute, Centers for Disease Control and Prevention... |
 |
Myelodysplastic Syndromes: Clinical and Biological Advances by Peter L. Greenberg (Author) This book describes the clinical classification, underlying biological mechanisms and treatment of the myelodysplastic syndromes. Authored by international experts, the chapters cover all aspects of the myelodysplastic syndromes, from an in-depth analysis of the multifactorial nature of this disease, including an assessment of stromal, immunological and stem cell abnormalities, to a review of recent molecular and cytogenetic discoveries and insights. This book will be a valuable resource to clinicians and researchers who wish to learn more about myelodysplastic syndromes. |
 |
Cure Myelodysplastic Syndromes T-shirt Large White by Shop Zeus |
 |
Myelodysplastic Syndromes (Hematologic Malignancies) by H.J. Deeg (Author), D.T. Bowen (Author), S.D. Gore (Author), T. Haferlach (Author), M.M. Le Beau (Author), C. Niemeyer (Author) This book summarizes our current knowledge of MDS, from very basic aspects to the clinical management. It provides guidance to the diagnosis, an understanding of disease mechanisms, and a discussion of treatment strategies. |
 |
Fight Against Myelodysplastic Syndromes Mug by Design a Product LLC Text on mug: Fight Against Myelodysplastic Syndromes * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
 |
The Myelodysplastic Syndromes: Pathobiology and Clinical Management (Basic & Clinical Oncology, 27) by John Bennett (Editor) Univ. of Rochester, NY. Illustrates the success of the relationship between basic and clinical science as demonstrated by new insights into clinical drug resistance and means of circumventing this potential obstacle to effective cancer treatment. |
| © 2009 BrightSurf.com |